Please login to the form below

Not currently logged in
Email:
Password:

Nabriva

This page shows the latest Nabriva news and features for those working in and with pharma, biotech and healthcare.

Pharma deals for June 2012

Pharma deals for June 2012

Nabriva Therapeutics and Forest Laboratories announced a collaborative partnership whereby Forest will fund and help develop Nabriva's novel class pleuromutilin BC-3781 for the treatment of serious skin infections and ... Nabriva will receive an upfront

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Nabriva Therapeutics appoints chief medical officer. Jennifer Schranz will lead the company’s clinical development business. ... Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and

  • Nabriva Therapeutics appoints new chief commercial officer Nabriva Therapeutics appoints new chief commercial officer

    Nabriva Therapeutics appoints new chief commercial officer. Francesco Maria Lavino joins to support commercialisation of its new antibiotic. ... He said: “Nabriva Therapeutics is poised to introduce what is potentially the first new class of

  • F2G appoints chief financial officer F2G appoints chief financial officer

    F2G appoints chief financial officer. Ralf Schmid brings experience from Nabriva Therapeutics. ... He moves to F2G from Nabriva Therapeutics, where he had been a member of the management board since the Austrian biopharmaceutical company's inception in

  • Dr David Chiswell joins Kymab Dr David Chiswell joins Kymab

    Dr Chiswell currently serves as chairman of Albireo Pharma, a Swedish biopharmaceutical company, and is a director of Nabriva Therapeutics, an Austrian biopharmaceutical firm.

  • Nabriva Therapeutics adds Will Sargent to team Nabriva Therapeutics adds Will Sargent to team

    Nabriva Therapeutics adds Will Sargent to team. Join as VP of commercial strategy and investor relations. ... Nabriva Therapeutics has appointed Will Sargent in the newly created position of vice president of commercial strategy and investor relations.

More from appointments
Approximately 4 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics